Clinical Significance of Lung V5% in Radiation Therapy
The clinical significance of lung V5% (volume receiving ≥5 Gy) remains uncertain and requires additional evaluation, as it is not yet established as a standard constraint for conventional fractionation, though emerging evidence suggests it may predict radiation pneumonitis risk, particularly in hypofractionated and stereotactic regimens. 1
Current Guideline Position on V5%
The European Organisation for Research and Treatment of Cancer (EORTC) explicitly states that "the precise value of other parameters, such as the V5, requires additional evaluation" for conventional fractionation schedules (approximately 2 Gy per fraction). 1 This guideline prioritizes V20 (≤35-37%) and mean lung dose (MLD ≤20-23 Gy) as the established dose-volume constraints that correlate with radiation pneumonitis risk. 1
V20 and MLD remain the primary, validated constraints for lung organ-at-risk planning in conventional fractionation. 1
Emerging Evidence for V5% Significance
Hypofractionated Radiotherapy (4 Gy per fraction)
Recent research demonstrates that V5% becomes clinically relevant in hypofractionated regimens:
- In patients receiving 60-72 Gy in 4 Gy fractions, V5 <41.3% was associated with <20% risk of grade ≥2 radiation pneumonitis. 2
- Patients who developed grade ≥2 pneumonitis had significantly higher V5 values (mean 49.6% vs 40.6%, P=0.01). 2
- However, V5 was identified as a lower-priority constraint compared to V20 <17.7% in multivariable analysis. 2
Stereotactic Body Radiotherapy (SBRT)
For SBRT/SABR treatments, V5% emerges as a critical predictor:
- Total lung V5 and contralateral lung V5 were the best predictors of radiation pneumonitis (p <0.0001 for both) following SBRT. 3
- The 10% risk level for grade 2-3 pneumonitis corresponded to total lung V5 of 27.9% and contralateral lung V5 of 21.8%. 3
Intensity-Modulated Radiotherapy (IMRT)
The introduction of V5 constraints in IMRT planning has shown clinical impact:
- Adding V5 ≤60% as a dose constraint significantly reduced fatal pneumonitis from 16% to 4% (p=0.05) in locally advanced NSCLC patients treated with IMRT. 4
- This constraint reduced lung volume receiving doses ≤20 Gy from 51% to 41% (p <0.0001). 4
Helical Tomotherapy
In hypofractionated treatments using helical tomotherapy:
- V5 was the only independent predictor of symptomatic radiation pneumonitis on multivariate analysis (p=0.019). 5
- V5 demonstrated the highest predictive power with an area under curve of 0.780 (p=0.004). 5
- The threshold value of V5 for symptomatic pneumonitis development was 65%. 5
Mediastinal Lymphoma
For mediastinal radiation in lymphoma patients:
- V5 >55% was strongly associated with increased pneumonitis risk (OR: 7.01; 95% CI, 2.94-16.72; p <0.001). 6
- Patients achieving both MLD ≤13.5 Gy and V5 ≤55% had only 8% pneumonitis risk, compared to 48% when constraints were not met. 6
Clinical Application Algorithm
For conventional fractionation (2 Gy/fraction):
- Prioritize V20 ≤35-37% and MLD ≤20-23 Gy as primary constraints 1
- V5 should not be used as a standard constraint pending further validation 1
For hypofractionated radiotherapy (4 Gy/fraction):
For SBRT/SABR:
- Target total lung V5 <27.9% for 10% risk of grade 2-3 pneumonitis 3
- Consider contralateral lung V5 <21.8% 3
For IMRT in locally advanced NSCLC:
- Implement V5 ≤60% constraint to reduce fatal pneumonitis risk 4
For helical tomotherapy hypofractionation:
- Maintain V5 <65% to prevent symptomatic pneumonitis 5
Critical Caveats
- Patient factors (lung function, age, sex) do not adequately select high-risk patients for radiation pneumonitis. 1
- Approximately 10-15% of patients may still develop severe toxicity even with doses much lower than established thresholds. 1
- Patients with idiopathic interstitial pneumonitis have high risk of severe and potentially lethal radiation pneumonitis regardless of dose constraints. 1
- V5 constraints require additional validation before incorporation into standard clinical practice or trial planning guidelines. 2